BiomX Inc.

PHGE
$0.62 (- $0.06 - 8.37%)
Last updated: 2026-06-10 18:50 UTC
PHGE Metrics
Exchange
🇺🇸 NYSE XASE
NYSE Mkt LLCUnited StatesAmerica/New_York
SectorHealthcare
IndustryBiotechnology
ISINUS09090D5095
CUSIP09090D509
Market Price0.62
Dividend Yield N/A
Dividend Growth
1YN/A
3YN/A
5YN/A
10YN/A
Annual Dividend N/A
Latest Payout ($)N/A
Latest Payout DateN/A
Dividend FrequencyNone
P/E RatioN/A
EPS-35.8
Market Cap$3.1M
Book Value-5.76
Price to Book-0.347
Beta1.57
52w High22.06
52w Low1.5
Next Earnings DateN/A

BiomX Inc. trades under ticker PHGE on NYSE as a stock. Use this page to review stock price, dividends, and price history. The page also shows Healthcare exposure. Identifiers: ISIN US09090D5095, CUSIP 09090D509.

About the Company
BiomX Inc., a clinical-stage biopharmaceutical company, develops products using natural and engineered phage technologies designed to target and kill specific harmful bacteria associated with chronic diseases. The company is developing BX211, a phage therapy, which is in phase 2 clinical study for the treatment of diabetic foot osteomyelitis. It also developing BX004, a phage therapy for cystic fibrosis and non-cystic fibrosis bronchiectasis patients with chronic pulmonary infections caused by Pseudomonas aeruginosa that is in Phase 1b/2a clinical trials. The company was founded in 2015 and is headquartered in Ness Ziona, Israel.
Price History